IL241059B - A single high dose of mva to induce a protective immune response in newborns and infants - Google Patents

A single high dose of mva to induce a protective immune response in newborns and infants

Info

Publication number
IL241059B
IL241059B IL241059A IL24105915A IL241059B IL 241059 B IL241059 B IL 241059B IL 241059 A IL241059 A IL 241059A IL 24105915 A IL24105915 A IL 24105915A IL 241059 B IL241059 B IL 241059B
Authority
IL
Israel
Prior art keywords
neonates
infants
immune response
high dose
protective immune
Prior art date
Application number
IL241059A
Other languages
English (en)
Hebrew (he)
Other versions
IL241059A0 (en
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of IL241059A0 publication Critical patent/IL241059A0/en
Publication of IL241059B publication Critical patent/IL241059B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
IL241059A 2013-03-15 2015-09-02 A single high dose of mva to induce a protective immune response in newborns and infants IL241059B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361788722P 2013-03-15 2013-03-15
PCT/EP2014/000693 WO2014139687A1 (en) 2013-03-15 2014-03-14 Single high dose of mva induces a protective immune response in neonates and infants

Publications (2)

Publication Number Publication Date
IL241059A0 IL241059A0 (en) 2015-11-30
IL241059B true IL241059B (en) 2020-10-29

Family

ID=50389388

Family Applications (1)

Application Number Title Priority Date Filing Date
IL241059A IL241059B (en) 2013-03-15 2015-09-02 A single high dose of mva to induce a protective immune response in newborns and infants

Country Status (17)

Country Link
US (1) US9707291B2 (enExample)
EP (2) EP2968524A1 (enExample)
JP (1) JP6480875B2 (enExample)
KR (1) KR102269491B1 (enExample)
CN (1) CN105101993A (enExample)
AU (4) AU2014231229A1 (enExample)
BR (1) BR112015021781A2 (enExample)
CA (1) CA2905569C (enExample)
EA (1) EA034825B1 (enExample)
HK (1) HK1216860A1 (enExample)
IL (1) IL241059B (enExample)
MX (1) MX376293B (enExample)
MY (1) MY175269A (enExample)
SG (2) SG10201707340XA (enExample)
UA (1) UA126785C2 (enExample)
WO (1) WO2014139687A1 (enExample)
ZA (1) ZA201507017B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034825B1 (ru) * 2013-03-15 2020-03-25 Бавариан Нордик А/С Разовые высокие дозы mva индуцируют защитный иммунный ответ у новорожденных и младенцев
WO2015136056A1 (en) 2014-03-12 2015-09-17 Bavarian Nordic A/S Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus
US20230233670A1 (en) * 2020-06-10 2023-07-27 Bavarian Nordic A/S A Recombinant Modified Vaccinia Virus (MVA) Vaccine Against Coronavirus Disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9117596D0 (en) * 1991-08-15 1991-10-02 John Gibson Lifting Gear Ltd Pulling system
US5471902A (en) * 1994-02-22 1995-12-05 Athenry Enterprises Limited Tuning system for pianos
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
HU230198B1 (hu) * 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
EP1420822B2 (en) 2002-04-19 2017-07-05 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7501127B2 (en) * 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
CN101128217B (zh) * 2005-02-23 2012-04-25 巴法里安诺迪克有限公司 改良的痘病毒快速诱导抗痘病毒或其它传染物的免疫力的用途
CA2662730A1 (en) * 2006-09-08 2008-03-13 Bavarian Nordic A/S Phenotypic and genotypic differences of mva strains
US20110052627A1 (en) * 2008-06-20 2011-03-03 Paul Chaplin Recombinant modified vaccinia virus measles vaccine
JP2013507107A (ja) * 2009-10-08 2013-03-04 バヴァリアン・ノルディック・アクティーゼルスカブ Ｈｉｖに対するヒトにおける広範なｔ細胞応答の生成
US9463238B2 (en) * 2011-12-09 2016-10-11 Bavarian Nordic A/S Recombinant poxvirus vector comprising tetanus toxin fragment C
US10111946B2 (en) * 2012-06-22 2018-10-30 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
SI2879702T1 (sl) * 2012-08-01 2020-02-28 Bavarian Nordic A/S Cepivo na osnovi rekombinantnega modificiranega virusa vakcinacije Ankara (MVA) proti respiratornemu sincitialnemu virusu (RSV)
EA034825B1 (ru) * 2013-03-15 2020-03-25 Бавариан Нордик А/С Разовые высокие дозы mva индуцируют защитный иммунный ответ у новорожденных и младенцев

Also Published As

Publication number Publication date
MX2015011388A (es) 2016-02-03
EP3708187A1 (en) 2020-09-16
JP6480875B2 (ja) 2019-03-13
NZ711569A (en) 2021-03-26
AU2020260472A1 (en) 2020-11-26
IL241059A0 (en) 2015-11-30
ZA201507017B (en) 2018-12-19
JP2016514114A (ja) 2016-05-19
BR112015021781A2 (pt) 2017-07-18
HK1216860A1 (zh) 2016-12-09
SG11201507192SA (en) 2015-10-29
US9707291B2 (en) 2017-07-18
AU2019200977A1 (en) 2019-02-28
EA201591803A1 (ru) 2016-02-29
UA126785C2 (uk) 2023-02-08
AU2014231229A1 (en) 2015-09-17
AU2022235527B2 (en) 2023-10-26
CN105101993A (zh) 2015-11-25
CA2905569A1 (en) 2014-09-18
KR20150129027A (ko) 2015-11-18
SG10201707340XA (en) 2017-10-30
MY175269A (en) 2020-06-17
KR102269491B1 (ko) 2021-06-25
US20160030551A1 (en) 2016-02-04
EP2968524A1 (en) 2016-01-20
EA034825B1 (ru) 2020-03-25
AU2022235527A1 (en) 2022-10-13
WO2014139687A1 (en) 2014-09-18
CA2905569C (en) 2023-07-25
MX376293B (es) 2025-03-07

Similar Documents

Publication Publication Date Title
PT3578054T (pt) Preparação e incorporação de coprodutos em bebidas para melhorar os atributos nutricionais e sensoriais
EP2986133A4 (en) IMPROVED EXTRACTS OF FOOD AND BEVERAGE COMPONENTS
ZA201506419B (en) Enhanced transgene expression and processing
SG11201507655RA (en) Myceliated coffee products and methods for making
IL242907B (en) Hydrocarbon vaccine preparations for stimulating immune responses and their uses in cancer treatment
PL2991511T3 (pl) Dający się odparować materiał i kapsułka
EP2959447A4 (en) PURCHASE OF PHYSICAL AND VIRTUAL PRODUCTS
ZA201506496B (en) Plant regulatory elements and uses thereof
ZA201506453B (en) Plant regulatory elements and uses thereof
PL2922557T3 (pl) Suplementy ziołowe i sposoby ich zastosowania
GB2515865B (en) Use of galactooligosaccharides in therapy
GB2533746B (en) Milk powder box and milk brewing device
IL244354A0 (en) Flu vaccine and treatment
IL262797B (en) Preparation and use of a composition for prevention and mitigation of the effects of radiation
ZA201607581B (en) Dosage forms and therapeutic uses l-4lchlorokynurenine
GB201320483D0 (en) Methods and apparatus relating to beverage capsules
PL2846648T3 (pl) Formuła dla niemowląt i jej otrzymywanie
ZA201507017B (en) Single high dose of mva induces a protective immune response in neonates and infants
GB201407760D0 (en) Vaporisable material and capsule
GB2522146B (en) Use of Gynura divaricata in Preparing Medicaments or Food for Treating Hepatitis
GB201421363D0 (en) Peptides inducing an immune response against copepods and/or the development of a mucous shield in fish;
GB201312168D0 (en) Animal and child safety lead
GB201319509D0 (en) Size and length adjustable sleep suit for babies
TWM475882U (en) Neck pillow device of chair
PT2928324T (pt) Composição e utilização de um suplemento alimentar.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed